An increased reporting of shigellosis cases, mainly caused by Shigella sonnei, among travellers returning from Cabo Verde has been ongoing in the European Union/European Economic Area (EU/EEA), the United Kingdom (UK), and the United States (US) since September 2022. This outbreak evolved rapidly during November and December 2022.
This document assesses the risk of further spread of S. sonnei amongst MSM and in the broader population in EU/EEA countries, resulting from the current increase in extensively-drug resistant S. sonnei infections.
Following the occurrence of several hospital-acquired malaria cases in the European Union (EU), ECDC has assessed the risk related to transmission of the parasite in hospital settings.
The occurrence of shigellosis among refugees is not unexpected because shigellosis is endemic in the countries they originate from, as well as in some of the countries they travel through.
This rapid risk assessment assesses the specific risk related to importation and spread of vector borne diseases in the context of a large number of migrants to the EU. It does not cover other health needs for these populations.
Locally acquired cases of malaria have been occurring in Greece since 2009, with the highest numbers reported in 2011. In 2012, local malaria transmission was still ongoing, but fewer cases were reported.
The assessment teams reviewed the risks of potential re-establishment of malaria transmission in Greece, and proposed prevention measures in the specific areas concerned and across the country.
The ECDC risk, as assessed on 23 August 2011, remains unchanged. The main risk is to persons residing in, visiting and working in the affected areas of Greece, particularly Evrotas in Lakonia. The risk for further extension of malaria transmission into the EU as a result of this event is considered low at present. EU national blood competent authorities should be considering whether to implement deferral measures for persons returning from these specific affected areas in Greece, taking into consideration measures currently implemented by the Greek blood safety authorities and after a considered risk assessment in collaboration with their national public health authorities.
Greece reports six cases of Plasmodium vivax infection in Evrotas, Lakonia, Peloponnese region, and Chalkida in Evoia since June 2011. The main risk related to the current event is to persons living in, visiting and working in the particular area of Evrotas in the district of Lakonia (and potentially Chalkida in Evoia, though more information is needed) in Greece.